Medidata Cloud Securely Manages Echocardiogram Images for Global Heart Measurement Study
NEW YORK – October 9, 2018 - Medidata (NASDAQ: MDSO) today announced that Medidata Cloud, the Intelligent Platform for Life Sciences, is streamlining the management of medical images for the World Alliance of Societies of Echocardiography (WASE) Normal Values Study. WASE is the first study of its kind to measure heart dimension and function across countries, geographical regions, cultures, gender, and age to benchmark differences based on diversity.
The WASE study shares a high number of echocardiogram (echo) files across continents and countries. Echo files are large and require specialized and secure technology. The study leverages Medidata Rave Imaging to:
- De-identify, acquire, transmit and store all echo images from sites globally
- Simplify the management and sharing of images among doctors participating in the study
“We know the importance of diversity in clinical trials, and this study is a key factor in forwarding that goal and benchmarking differences in heart size and function,” said Federico M. Asch, MD, FASE, MedStar Health Research Institute in Washington, DC. “We look forward to presenting the WASE data next year, and strongly believe it will inform approaches based on diversity factors.”
Launched in June 2016, the WASE study is funded by the American Society of Echocardiography (ASE) Foundation and supported by Medidata, the MedStar Health Research Institute, University of Chicago and TOMTEC Imaging Systems. Its purpose is to create a global database of normal heart values to inform and potentially change the standard of care for a broad range of cardiovascular paradigms based on diversity criteria. To date, the study enrolled more than 2,000 subjects in six continents and 18 countries.
“We’re proud our platform is powering this important study, enabling global collaboration, and helping to achieve diversity in clinical research,” said Glen de Vries, co-founder and president, Medidata.
About WASE Study
The World Alliance of Societies of Echocardiography (WASE) Normal Values Study was launched in 2016 and has centers in six continents and 18 countries, including the Argentina, Australia, Belgium, Brazil, Canada, China, France, India, Indonesia, Iran, Italy, Japan, Korea, Mexico, Nigeria, Philippines, United Kingdom and United States. The study is funded by the American Society of Echocardiography (ASE) Foundation and sponsored by Medidata, the MedStar Health Research Institute, University of Chicago and TOMTEC Imaging Systems. To date, the study has reached over 2,000 enrolled subjects and the final results will be shared in 2019.
About Medidata
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users everyday to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
About MedStar Health Research Institute
The MedStar Health Research Institute is the research arm of MedStar Health, the largest healthcare provider in Maryland and the Washington, D.C., region. MHRI provides scientific, administrative and regulatory support for research programs throughout the MedStar Health system. MHRI’s expertise includes translational research into disease prevention, diagnosis and treatment. These programs complement the key clinical services and teaching programs in the 10 MedStar hospitals and other MedStar entities. For more information, visit www.MedStarResearch.org.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
